Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim

Key Points

• Guggenheim reiterated a "Buy" on Zentalis with a $6 price target124.7% upside
• The stock opened at $2.67 with a market capitalization of roughly $192.9 million and a one‑year trading range of $1.01 to $3.95, with 50‑ and 200‑day SMAs near $2.58 and $1.94 respectively.
• Group Walters made a large insider purchase of 6,459,973 shares at $1.20 (raising its holdings to 13,509,973 shares, a 91.6% increase), while other insiders have trimmed positions—insiders now own about 1.90% of the company.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at Guggenheim in a report issued on Friday,Benzinga reports. They currently have a $6.00 price target on the stock. Guggenheim's price target suggests a potential upside of 124.72% from the stock's current price.

Separately, Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an "equal weight" rating and a $5.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $5.17.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock opened at $2.67 on Friday. The company has a market capitalization of $192.91 million, a PE ratio of -1.29 and a beta of 1.71. The company has a 50-day simple moving average of $2.58 and a two-hundred day simple moving average of $1.94. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $3.95.

Insider Buying and Selling

In related news, major shareholder Group Walters purchased 6,459,973 shares of the firm's stock in a transaction that occurred on Wednesday, December 31st. The shares were purchased at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the purchase, the insider owned 13,509,973 shares of the company's stock, valued at $16,211,967.60. This represents a 91.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Vincent Vultaggio sold 29,951 shares of the firm's stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the transaction, the insider owned 156,779 shares in the company, valued at approximately $380,972.97. This trade represents a 16.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 46,617 shares of company stock worth $113,417 in the last quarter. 1.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Sivia Capital Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $27,000. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at about $37,000. Corient Private Wealth LLC acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at about $41,000. Voleon Capital Management LP purchased a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $41,000. Finally, SG Americas Securities LLC grew its stake in shares of Zentalis Pharmaceuticals by 35.3% in the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company's stock valued at $48,000 after buying an additional 8,236 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.